Ballard Spahr says the Hikma v. Amarin decision makes it harder for brand-name drugmakers to sue over "skinny label" generics — a shift likely to speed generic competition and lower costs for patients
Related to this article
CMS chief says outcomes-based pay can help patients while finally ending physicians' box-checking frustration.
What new EBRI research on 401(k) borrowers means for doctors still paying off med school
Preparing rural care teams for AI can strengthen care without replacing clinical judgement.
The 3-part federal plan targets costs, red tape and corporate consolidation across commercial health insurance.
Revenue per patient is a common way to split practice profit. It’s also the wrong way.
Advertisement
Advertisement
Trending on Medical Economics
1
On National Physician Suicide Awareness Day 2026, 71% of physicians say mental health stigma persists
2
Michigan man charged with billing Medicare for psychotherapy never provided; women less likely than men to receive intensive treatment; gambling disorder emergency visits nearly doubled in Ontario — Morning Medical Update
3
59% of health care workers plan to look for a new job in the next year, Harris Poll finds
4
Georgetown report calls for capping hospital prices, reforming prior authorization and curbing medical debt
5